Menu Search
Equities

Annovis Bio Inc

07X:FRA

Annovis Bio Inc

Actions
  • Price (EUR)8.89
  • Today's Change1.91 / 27.36%
  • Shares traded400.00
  • 1 Year change-30.66%
  • Beta--
Data delayed at least 15 minutes, as of May 15 2024 14:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.

  • Revenue in USD (TTM)0.00
  • Net income in USD-56.20m
  • Incorporated2008
  • Employees6.00
  • Location
    Annovis Bio Inc101 LINDENWOOD DRIVE, SUITE 225MALVERN 19355United StatesUSA
  • Phone+1 (484) 875-3192
  • Fax+1 (610) 727-4001
  • Websitehttps://www.annovisbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.